A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: A study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry

Annals of the Rheumatic Diseases

Volumn 71, Issue 6, 2012, Pages 845-850

  Schipper, Lydia G ^a   Vermeer, Marloes ^b   Kuper, Hillechiena H ^b   Hoekstra, Monique O ^c   Haagsma, Cees J ^d   Den Broeder, Alfons A ^e   Van Riel, Piet ^a   Fransen, Jaap ^a   Van De Laar, Mart A F J ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c ISALA HOSPITAL   (Netherlands)

^d TWENTEBORG HOSPITAL   (Netherlands)

^e SINT MAARTENSKLINIEK   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE 28; DISEASE DURATION; DISEASE REGISTRY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EARLY INTERVENTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AMBULATORY CARE FACILITIES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NETHERLANDS; REGISTRIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SULFASALAZINE;

EID: 84860895505     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200274     Document Type: Article

References (38)

1. Breedveld FC. Current and future management approaches for rheumatoid arthritis. Arthritis Res 2002;4 Suppl 2:S16-21.
2. Smolen JS, Aletaha D, Machold KP. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19:163-77. (Pubitemid 40003947)
3. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45. (Pubitemid 46044858)
4. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
5. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43:906-14. (Pubitemid 38996967)
6. Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004;50:2072-81. (Pubitemid 38924384)
7. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73. (Pubitemid 29219206)
8. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90. (Pubitemid 41612204)
9. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
10. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
11. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18. (Pubitemid 27351112)
12. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9. (Pubitemid 38942816)
13. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9. (Pubitemid 350032650)
14. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010;69:65-9.
15. Kiely PD, Brown AK, Edwards CJ, et al. Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology (Oxford) 2009;48:765-72.
16. Klarenbeek NB, Allaart CF, Kerstens PJ, et al. The BeSt story: on strategy trials in rheumatoid arthritis. Curr Opin Rheumatol 2009;21:291-8.
17. Bakker MF, Jacobs JW, Verstappen SM, et al. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007;66 (Suppl 3):iii56-iii60. (Pubitemid 350032636)
18. Schipper LG, Van Hulst LTC, Grol R, et al. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolised treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford). 2010;49:2154-64.
19. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003;48:313-18. (Pubitemid 36277997)
20. Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006;54:3399-407. (Pubitemid 44737150)
21. Kuper I, Hoekstra M, ten Klooster P, et al. Remission can be achieved in 50% of early rheumatoid arthritis patients after 25 weeks in daily clinical practice. Ann Rheum Dis 2008;67(Suppl II):48.
22. Welsing PM, van Riel PL. The Nijmegen inception cohort of early rheumatoid arthritis. J Rheumatol Suppl 2004;69:14-21. (Pubitemid 38327486)
23. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
24. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007;66 Suppl 3:iii2-22.
25. Schipper LG, Hoekstra M, Vliet Vlieland TP, et al. [Practice guideline 'Diagnosis and treatment of rheumatoid arthritis']. Ned Tijdschr Geneeskd 2009;153:A944.
26. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
27. Zandbelt MM, Welsing PM, van Gestel AM, et al. Health Assessment Questionnaire modifications: is standardisation needed? Ann Rheum Dis 2001;60:841-5. (Pubitemid 32778174)
28. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
29. Söderlin MK, Bergman S. Absent "Window of Opportunity" in Smokers with Short Disease Duration. Data from BARFOT, a Multicenter Study of Early Rheumatoid Arthritis. J Rheumatol 2011;38:2160-8.
30. Smolen JS, Aletaha D. What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol 2006;24(Suppl 43):S7-S13. (Pubitemid 44696862)
31. Molenaar ET, Voskuyl AE, Dinant HJ, et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004;50:36-42. (Pubitemid 38084285)
32. Mäkinen H, Hannonen P, Sokka T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exp Rheumatol 2006;24(6 Suppl 43):S-22-8.
33. Sokka T, Mäkinen H. Drug management of early rheumatoid arthritis - 2008. Best Pract Res Clin Rheumatol 2009;23:93-102.
34. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
35. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-34. (Pubitemid 351651555)
36. van der Kooij SM, Allaart CF, Dijkmans BA, et al. Innovative treatment strategies for patients with rheumatoid arthritis. Curr Opin Rheumatol 2008;20:287-94. (Pubitemid 351483318)
37. Mäkinen H, Kautiainen H, Hannonen P, et al. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005;64:1410-13. (Pubitemid 41623849)
38. Landewé R, van der Heijde D, van der Linden S, et al. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 2006;65:637-41.